Tag Archive for: Claudin

The fibrotic signaling of overexpressed Claudin-1 can be inhibited with the Alentis antibody which helps diminishing collagen bundles in extracellular matrix tissueAlentis Therapeutics
Fibrotic tissues

CSL backs Swiss Alentis’ claudin-1 bet with up to $1.6bn deal

Australian biopharma company CSL has entered an exclusive global partnership with Basel-based Alentis Therapeutics to co-develop and co-commercialize lixudebart, an investigational antibody targeting claudin-1. CSL will pay Alentis $355 million upfront and the Swiss biotech is eligible for up to another $1.2 billion in commercial milestone payments. Once the drug reaches the market, global profits will be split 55% to CSL and 45% to Alentis. What is the deal all about?

Read more
Illustrative look at the tight junctions of cell-cell interaction (provided by SYnAbs S.A.) © SYnAbs S.A.
Swiss

Mega Series C in Switzerland

Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting Claudin-1 (CLDN1). The molecule is significantly involved in the tight junction between cells. Now the company closed a three digit million Seriec C round.

Read more